tudociclib   Click here for help

GtoPdb Ligand ID: 14631

Synonyms: Example 1 [WO2023172921]
Compound class: Synthetic organic
Comment: Tudociclib is the INN for a cyclin dependent kinase inhibitor, that was included in WHO INN Proposed List 135 (July 2026). The compound is the principal claim within patent WO2023172921A1 (Incyte), where it is described as a CDK2 inhibitor [1]. This makes it likely that tudociclib is the INN for Incyte's lead CDK2 inhibitor INCB123667 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 119.37
Molecular weight 419.5
XLogP 1.78
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC1=C(C=CN2C1=NC(=N2)N[C@H]3CCN(C[C@H]3C)S(=O)(=O)C)C4=CNN=C4
Isomeric SMILES CCOC1=C(C=CN2C1=NC(=N2)N[C@H]3CCN(C[C@H]3C)S(=O)(=O)C)C4=CNN=C4
InChI InChI=1S/C18H25N7O3S/c1-4-28-16-14(13-9-19-20-10-13)5-8-25-17(16)22-18(23-25)21-15-6-7-24(11-12(15)2)29(3,26)27/h5,8-10,12,15H,4,6-7,11H2,1-3H3,(H,19,20)(H,21,23)/t12-,15+/m1/s1
InChI Key OUUNYSHRNVQOAH-DOMZBBRYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
INCB123667 was progressed as a clinical anti-tumour agent.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07023627 A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Phase 2 Interventional Incyte Corporation
NCT07214779 Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Phase 3 Interventional Incyte Corporation